Under construction – not a live service
Sign in
Taking peoplePhase 3

Tests teclistamab and talquetamab with standard drugs in newly diagnosed multiple myeloma

Compares teclistamab or talquetamab with daratumumab and lenalidomide against standard treatment in myeloma.

Plain-language title generated from the registry record
Registry title: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Key facts

Where
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, and Zhengzhou, ChinaSee the 32 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which of these best describes your myeloma treatment so far?
  • Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
  • Which describes how well you can look after yourself?
  • Have you ever had a stem cell transplant using your own cells?

Source: NCT05552222, who can take part

Where in China

  • Beijing Tongren Hospital CMUBeijing, ChinaNo longer taking part
  • Peking Union Medical College HospitalBeijing, ChinaNo longer taking part
  • Peking University First HospitalBeijing, ChinaNo longer taking part
  • The First Hospital of Jilin UniversityChangchun, ChinaNo longer taking part
  • The Second Xiangya Hospital of Central South HospitalChangsha, ChinaNo longer taking part
  • Changzhou No 2 Peoples HospitalChangzhou, ChinaNo longer taking part
  • Beijing Chaoyang HospitalChaoyang District, ChinaNo longer taking part
  • Sichuan Provincial Peoples HospitalChengdu, ChinaNo longer taking part
  • Chongqing University Cancer HospitalChongqing, ChinaNo longer taking part
  • Fujian Meidical University Union HospitalFuzhou, ChinaNo longer taking part
  • Nanfang HospitalGuangzhou, ChinaNo longer taking part
  • Sun Yat-sen University Cancer CenterGuangzhou, ChinaNo longer taking part
  • No.1 Affiliated Hospital, Medical College of Zhejiang UniversityHangzhou, ChinaNo longer taking part
  • The Second Affiliated Hospital of Zhejiang UniversityHangzhou, ChinaNo longer taking part
  • Harbin Medical University Cancer HospitalHarbin, ChinaNo longer taking part
  • Qilu Hospital of Shandong UniversityJinan, ChinaNo longer taking part
  • The First Affliated Hospital Of Nanchang UniversityNanchang, ChinaNo longer taking part
  • Nanjing Drum Tower hospitalNanjing, ChinaNo longer taking part
  • Zhongda Hospital Southeast UniversityNanjing, ChinaNo longer taking part
  • The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaNo longer taking part
  • Renji Hospital, Shanghai Jiaotong University School of MedicineShanghai, ChinaNo longer taking part
  • Ruijin Hospital Shanghai Jiao Tong UniversityShanghai, ChinaNo longer taking part
  • Shanghai Fourth People's HospitalShanghai, ChinaNo longer taking part
  • Shengjing Hospital Of China Medical UniversityShenyang, ChinaNo longer taking part
  • Peking University Shenzhen HospitalShenzhen, ChinaNo longer taking part
  • Institute of Hematology and Blood Diseases HospitalTianjin, ChinaNo longer taking part
  • Tianjin Medical University Cancer Institute and HospitalTianjin, ChinaNo longer taking part
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNo longer taking part
  • Wuhan Tongji Hospital Tongji Medical CollegeWuhan, ChinaNo longer taking part
  • The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaNo longer taking part
  • The First Affiliated hospital of Xiamen UniversityXiamen, ChinaNo longer taking part
  • Henan Cancer HospitalZhengzhou, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Janssen Research & Development, LLC
Trial code
NCT05552222EU 2023-503442-30-00
Record updated
3 November 2026
Original description
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).Read full original descriptionShow less

A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Inclusion: Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria; Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment; Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment; A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment.

Exclusion: Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams [mg] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasone within 14 days before randomization; Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization; Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients; Myeloma Frailty Index of >=2 with the exception of participants who have a score of 2 based on age alone; Had plasmapheresis within 28 days of randomization; Known contraindications to the use of daratumumab or lenalidomide per local prescribing information.

ClinicalTrials.gov NCT05552222 · EU CTIS 2023-503442-30-00

Under construction, not live – A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (NCT05552222) – Frontlight Research